Multistrain influenza protection induced by a nanoparticulate mucosal immunotherapeutic

W. Tai, L. Roberts, A. Seryshev, J. M. Gubatan, C. S. Bland, R. Zabriskie, S. Kulkarni, Lynn Soong, I. Mbawuike, B. Gilbert, F. Kheradmand, D. B. Corry

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

All commercial influenza vaccines elicit antibody responses that protect against seasonal infection, but this approach is limited by the need for annual vaccine reformulation that precludes efficient responses against epidemic and pandemic disease. In this study we describe a novel vaccination approach in which a nanoparticulate, liposome-based agent containing short, highly conserved influenza-derived peptides is delivered to the respiratory tract to elicit potent innate and selective T cell-based adaptive immune responses. Prepared without virus-specific peptides, mucosal immunostimulatory therapeutic (MIT) provided robust, but short-lived, protection against multiple, highly lethal strains of influenza in mice of diverse genetic backgrounds. MIT prepared with three highly conserved epitopes that elicited virus-specific memory T-cell responses but not neutralizing antibodies, termed MITpep, provided equivalent, but more durable, protection relative to MIT. Alveolar macrophages were more important than dendritic cells in determining the protective efficacy of MIT, which induced both canonical and non-canonical antiviral immune pathways. Through activation of airway mucosal innate and highly specific T-cell responses, MIT and MITpep represent novel approaches to antiviral protection that offer the possibility of universal protection against epidemic and pandemic influenza.

Original languageEnglish (US)
Pages (from-to)197-207
Number of pages11
JournalMucosal Immunology
Volume4
Issue number2
DOIs
StatePublished - Mar 2011

Fingerprint

Human Influenza
Pandemics
T-Lymphocytes
Antiviral Agents
Viruses
Therapeutics
Peptides
Influenza Vaccines
Alveolar Macrophages
Adaptive Immunity
Neutralizing Antibodies
Liposomes
Respiratory System
Dendritic Cells
Antibody Formation
Epitopes
Vaccination
Vaccines
Infection

ASJC Scopus subject areas

  • Immunology
  • Immunology and Allergy

Cite this

Tai, W., Roberts, L., Seryshev, A., Gubatan, J. M., Bland, C. S., Zabriskie, R., ... Corry, D. B. (2011). Multistrain influenza protection induced by a nanoparticulate mucosal immunotherapeutic. Mucosal Immunology, 4(2), 197-207. https://doi.org/10.1038/mi.2010.50

Multistrain influenza protection induced by a nanoparticulate mucosal immunotherapeutic. / Tai, W.; Roberts, L.; Seryshev, A.; Gubatan, J. M.; Bland, C. S.; Zabriskie, R.; Kulkarni, S.; Soong, Lynn; Mbawuike, I.; Gilbert, B.; Kheradmand, F.; Corry, D. B.

In: Mucosal Immunology, Vol. 4, No. 2, 03.2011, p. 197-207.

Research output: Contribution to journalArticle

Tai, W, Roberts, L, Seryshev, A, Gubatan, JM, Bland, CS, Zabriskie, R, Kulkarni, S, Soong, L, Mbawuike, I, Gilbert, B, Kheradmand, F & Corry, DB 2011, 'Multistrain influenza protection induced by a nanoparticulate mucosal immunotherapeutic', Mucosal Immunology, vol. 4, no. 2, pp. 197-207. https://doi.org/10.1038/mi.2010.50
Tai W, Roberts L, Seryshev A, Gubatan JM, Bland CS, Zabriskie R et al. Multistrain influenza protection induced by a nanoparticulate mucosal immunotherapeutic. Mucosal Immunology. 2011 Mar;4(2):197-207. https://doi.org/10.1038/mi.2010.50
Tai, W. ; Roberts, L. ; Seryshev, A. ; Gubatan, J. M. ; Bland, C. S. ; Zabriskie, R. ; Kulkarni, S. ; Soong, Lynn ; Mbawuike, I. ; Gilbert, B. ; Kheradmand, F. ; Corry, D. B. / Multistrain influenza protection induced by a nanoparticulate mucosal immunotherapeutic. In: Mucosal Immunology. 2011 ; Vol. 4, No. 2. pp. 197-207.
@article{85f2ff7e2c4d4ababbdf87aa51763dfe,
title = "Multistrain influenza protection induced by a nanoparticulate mucosal immunotherapeutic",
abstract = "All commercial influenza vaccines elicit antibody responses that protect against seasonal infection, but this approach is limited by the need for annual vaccine reformulation that precludes efficient responses against epidemic and pandemic disease. In this study we describe a novel vaccination approach in which a nanoparticulate, liposome-based agent containing short, highly conserved influenza-derived peptides is delivered to the respiratory tract to elicit potent innate and selective T cell-based adaptive immune responses. Prepared without virus-specific peptides, mucosal immunostimulatory therapeutic (MIT) provided robust, but short-lived, protection against multiple, highly lethal strains of influenza in mice of diverse genetic backgrounds. MIT prepared with three highly conserved epitopes that elicited virus-specific memory T-cell responses but not neutralizing antibodies, termed MITpep, provided equivalent, but more durable, protection relative to MIT. Alveolar macrophages were more important than dendritic cells in determining the protective efficacy of MIT, which induced both canonical and non-canonical antiviral immune pathways. Through activation of airway mucosal innate and highly specific T-cell responses, MIT and MITpep represent novel approaches to antiviral protection that offer the possibility of universal protection against epidemic and pandemic influenza.",
author = "W. Tai and L. Roberts and A. Seryshev and Gubatan, {J. M.} and Bland, {C. S.} and R. Zabriskie and S. Kulkarni and Lynn Soong and I. Mbawuike and B. Gilbert and F. Kheradmand and Corry, {D. B.}",
year = "2011",
month = "3",
doi = "10.1038/mi.2010.50",
language = "English (US)",
volume = "4",
pages = "197--207",
journal = "Mucosal Immunology",
issn = "1933-0219",
publisher = "Nature Publishing Group",
number = "2",

}

TY - JOUR

T1 - Multistrain influenza protection induced by a nanoparticulate mucosal immunotherapeutic

AU - Tai, W.

AU - Roberts, L.

AU - Seryshev, A.

AU - Gubatan, J. M.

AU - Bland, C. S.

AU - Zabriskie, R.

AU - Kulkarni, S.

AU - Soong, Lynn

AU - Mbawuike, I.

AU - Gilbert, B.

AU - Kheradmand, F.

AU - Corry, D. B.

PY - 2011/3

Y1 - 2011/3

N2 - All commercial influenza vaccines elicit antibody responses that protect against seasonal infection, but this approach is limited by the need for annual vaccine reformulation that precludes efficient responses against epidemic and pandemic disease. In this study we describe a novel vaccination approach in which a nanoparticulate, liposome-based agent containing short, highly conserved influenza-derived peptides is delivered to the respiratory tract to elicit potent innate and selective T cell-based adaptive immune responses. Prepared without virus-specific peptides, mucosal immunostimulatory therapeutic (MIT) provided robust, but short-lived, protection against multiple, highly lethal strains of influenza in mice of diverse genetic backgrounds. MIT prepared with three highly conserved epitopes that elicited virus-specific memory T-cell responses but not neutralizing antibodies, termed MITpep, provided equivalent, but more durable, protection relative to MIT. Alveolar macrophages were more important than dendritic cells in determining the protective efficacy of MIT, which induced both canonical and non-canonical antiviral immune pathways. Through activation of airway mucosal innate and highly specific T-cell responses, MIT and MITpep represent novel approaches to antiviral protection that offer the possibility of universal protection against epidemic and pandemic influenza.

AB - All commercial influenza vaccines elicit antibody responses that protect against seasonal infection, but this approach is limited by the need for annual vaccine reformulation that precludes efficient responses against epidemic and pandemic disease. In this study we describe a novel vaccination approach in which a nanoparticulate, liposome-based agent containing short, highly conserved influenza-derived peptides is delivered to the respiratory tract to elicit potent innate and selective T cell-based adaptive immune responses. Prepared without virus-specific peptides, mucosal immunostimulatory therapeutic (MIT) provided robust, but short-lived, protection against multiple, highly lethal strains of influenza in mice of diverse genetic backgrounds. MIT prepared with three highly conserved epitopes that elicited virus-specific memory T-cell responses but not neutralizing antibodies, termed MITpep, provided equivalent, but more durable, protection relative to MIT. Alveolar macrophages were more important than dendritic cells in determining the protective efficacy of MIT, which induced both canonical and non-canonical antiviral immune pathways. Through activation of airway mucosal innate and highly specific T-cell responses, MIT and MITpep represent novel approaches to antiviral protection that offer the possibility of universal protection against epidemic and pandemic influenza.

UR - http://www.scopus.com/inward/record.url?scp=79951899244&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79951899244&partnerID=8YFLogxK

U2 - 10.1038/mi.2010.50

DO - 10.1038/mi.2010.50

M3 - Article

C2 - 20736998

AN - SCOPUS:79951899244

VL - 4

SP - 197

EP - 207

JO - Mucosal Immunology

JF - Mucosal Immunology

SN - 1933-0219

IS - 2

ER -